Abliva Past Earnings Performance
Past criteria checks 0/6
Abliva's earnings have been declining at an average annual rate of -8%, while the Biotechs industry saw earnings growing at 17.7% annually. Revenues have been declining at an average rate of 53.1% per year.
Key information
-8.0%
Earnings growth rate
37.7%
EPS growth rate
Biotechs Industry Growth | 0.7% |
Revenue growth rate | -53.1% |
Return on equity | -135.1% |
Net Margin | -69,714.6% |
Next Earnings Update | 23 May 2024 |
Recent past performance updates
Recent updates
Abliva (STO:ABLI) Is In A Strong Position To Grow Its Business
Dec 18Here's Why We're A Bit Worried About Abliva's (STO:ABLI) Cash Burn Situation
Aug 24Is Abliva (STO:ABLI) In A Good Position To Invest In Growth?
Aug 21We're Keeping An Eye On Abliva's (STO:ABLI) Cash Burn Rate
Oct 13Is Abliva (STO:ABLI) In A Good Position To Invest In Growth?
Mar 22How Much Is Abliva AB (publ) (STO:ABLI) Paying Its CEO?
Dec 06Revenue & Expenses BreakdownBeta
How Abliva makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 0 | -96 | 19 | 0 |
30 Sep 23 | 0 | -88 | 17 | 0 |
30 Jun 23 | 0 | -80 | 16 | 0 |
31 Mar 23 | 0 | -79 | 10 | 0 |
31 Dec 22 | 0 | -85 | 14 | 0 |
30 Sep 22 | 0 | -105 | 14 | 0 |
30 Jun 22 | 0 | -114 | 14 | 0 |
31 Mar 22 | 0 | -124 | 17 | 0 |
31 Dec 21 | 0 | -123 | 17 | 0 |
30 Sep 21 | 2 | -100 | 17 | 0 |
30 Jun 21 | 2 | -75 | 16 | 0 |
31 Mar 21 | 2 | -65 | 30 | 0 |
31 Dec 20 | 2 | -60 | 13 | 0 |
30 Sep 20 | 1 | -74 | 15 | 0 |
30 Jun 20 | 3 | -79 | 15 | 0 |
31 Mar 20 | 4 | -80 | 15 | 0 |
31 Dec 19 | 4 | -77 | 15 | 0 |
30 Sep 19 | 4 | -65 | 14 | 0 |
30 Jun 19 | 2 | -64 | 14 | 0 |
31 Mar 19 | 2 | -69 | 15 | 0 |
31 Dec 18 | 2 | -68 | 14 | 0 |
30 Sep 18 | 2 | -68 | 13 | 0 |
30 Jun 18 | 2 | -66 | 13 | 0 |
31 Mar 18 | 0 | -63 | 12 | 0 |
31 Dec 17 | 0 | -67 | 12 | 0 |
30 Sep 17 | 0 | -66 | 14 | 0 |
30 Jun 17 | 0 | -87 | 15 | 0 |
31 Mar 17 | 0 | -76 | 15 | 0 |
31 Dec 16 | 0 | -70 | 15 | 0 |
30 Sep 16 | 0 | -63 | 14 | 0 |
30 Jun 16 | 0 | -83 | 16 | 0 |
31 Mar 16 | 3 | -87 | 5 | 0 |
31 Dec 15 | 3 | -90 | 16 | 0 |
30 Sep 15 | 4 | -100 | 16 | 0 |
30 Jun 15 | 11 | -49 | 12 | 0 |
31 Mar 15 | 8 | -47 | 15 | 0 |
31 Dec 14 | 8 | -43 | 10 | 0 |
30 Sep 14 | 7 | -35 | 10 | 0 |
30 Jun 14 | 1 | -38 | 9 | 0 |
31 Mar 14 | 6 | -27 | 11 | 0 |
31 Dec 13 | 7 | -22 | 7 | 0 |
30 Sep 13 | 8 | -19 | 5 | 0 |
30 Jun 13 | 7 | -16 | 5 | 0 |
Quality Earnings: ABLI is currently unprofitable.
Growing Profit Margin: ABLI is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ABLI is unprofitable, and losses have increased over the past 5 years at a rate of 8% per year.
Accelerating Growth: Unable to compare ABLI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ABLI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.9%).
Return on Equity
High ROE: ABLI has a negative Return on Equity (-135.06%), as it is currently unprofitable.